Engineered cartilage from nasal septum cells is treating complex knee damage, thanks to Swiss researchers who developed the ...

SEN. Bong Go welcomed the initiative of the Philippine Health Insurance Corp. (PhilHealth) to provide coverage for surgeries ...

Phyllodes tumors are a rare type of breast growth. Less than 1% of all breast tumors are this type. Most are not cancer, called benign. But about 25% of these tumors are cancerous (or malignant).

Survival depends on many factors, so no one can tell you exactly how long you’ll live. It depends on your individual condition, type of cancer, treatment and level of fitness. Survival for testicular ...

Itchy skin, or pruritus, can be a symptom of some cancers, including blood-related, skin, liver, gallbladder, and bile-duct cancer cancers. However, other causes of itching are more common. Itching ...

The Number of Grants for each Cancer Type may include grants not 100% focused on that type of cancer. For example, a grant that focuses 90% on breast cancer and 10% on prostate cancer will be counted ...

Stage 4 cancer means cancer cells have spread to distant tissue or organs. The relative 5-year survival rate for a person receiving a diagnosis of stage 4 small cell lung cancer (SCLS) is 3% ...

What’s in a Pathology Report? Pathology reports can vary depending on what type of cancer you have. You may read about different tests and terms. But most reports usually have these sections.

Dietary supplements by themselves can’t fully treat cancer, but there are some supplements that can potentially help prevent cancer or assist in your cancer recovery. When it comes to dietary ...

away.” After this, the team worked with Dr. Sudhir Rawal, the medical director and chief of genito-uro oncology at the Rajiv Gandhi Cancer Institute and Research Center. Rawal performed several cases ...

A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. Fellow Japanese drugmaker Ono Pharmaceutical has won an FDA green light for vimseltinib to treat ...